Key result
CYP2C19 no-function alleles linked to ~2.3-fold higher MACCE with clopidogrel post-PCI.
Why the study?
The study was conducted to compare the clinical effectiveness of genotype-guided P2Y12 inhibitor selection following PCI in older patients (≥70 years) versus younger patients (<70 years).
Does CYP2C19 genotype-guided P2Y12 inhibitor selection affect the risk of MACCE differently in older (≥70 years) versus younger (<70 years) patients after PCI?
Cohort (n=1,469)
No
Does CYP2C19 genotype-guided P2Y12 inhibitor selection affect the risk of MACCE differently in older (≥70 years) versus younger (<70 years) patients after PCI?
CYP2C19 genotype-guided antiplatelet therapy after PCI provides important clinical benefits in both younger and older patients by identifying those at higher risk of MACCE when treated with clopidogrel.
Answers are grounded in this paper and cite their sources.
Extends CYP2C19-clopidogrel MACCE association to older PCI patients; leaves open genotype-guided P2Y12 benefits in this population.
AbstractStudy ObjectiveTo compare the clinical effectiveness of genotype‐guided P2Y12 inhibitor selection following PCI in older patients (≥70 years) and younger patients (<70 years).Design and SettingSingle‐center, retrospective, cohort study. Risk of major adverse cardiovascular or cerebrovascular events (MACCE), defined as stent thrombosis, ischemic stroke, transient ischemic attack, non‐fatal acute coronary syndrome, or cardiovascular death during 12 months after PCI, was compared across genotype and antiplatelet therapy groups by proportional hazards regression in patients ≥70 years and <70 years.Patients1,469 patients who underwent PCI and had CYP2C19 genotype testing at a single academic medical center.Measurements and Main ResultsThe study population was comprised of 402 (27.4%) ≥70 years (older group) and 1067 (72.6%) <70 years (younger group). Alternative P2Y12 inhibitors (prasugrel or ticagrelor) were used less often in the older group than the younger group in patients with a CYP2C19 no function allele (55% vs. 67%; p = 0.02) and in patients without a no function allele (10% vs. 35%, p < 0.001). For patients treated with clopidogrel, MACCE was significantly higher in no function allele carriers compared to those without a no function allele in the older group (19.2% vs. 12.7%; adjusted HR 2.32; 95% CI 1.07–5.05; p = 0.03) and the younger group (17.4% vs. 10.4%; adjusted HR 2.01; 95% CI 1.17–3.46; p = 0.01). In patients without a no function allele, MACCE risk was similar with clopidogrel compared to prasugrel or ticagrelor in the older group (adjusted HR 0.99; 95% CI 0.44–2.21; p = 0.98) and the younger group (adjusted HR 1.12; 95% CI 0.72–1.74; p = 0.61).ConclusionThis study suggests important clinical benefits of CYP2C19 genotype‐guided antiplatelet therapy after PCI in both younger and older patients.
No takes yet. Share an insight, caveat, or question.
Wood et al. (2021) conducted a cohort in Percutaneous coronary intervention (PCI) with coronary artery stent placement (n=1,469). CYP2C19 no function allele carriage in clopidogrel-treated patients (aged >=70 years) vs. No CYP2C19 no function allele in clopidogrel-treated patients (aged >=70 years) was evaluated on Major adverse cardiovascular or cerebrovascular events (MACCE: composite of stent thrombosis, ischemic stroke, transient ischemic attack, non-fatal acute coronary syndrome, or cardiovascular death) (HR 2.32, 95% CI 1.07-5.05, p=0.03). CYP2C19 no-function allele carriers on clopidogrel had higher MACCE vs non-carriers in older and younger PCI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: